Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 2,634

Document Document Title
WO/2018/102921A1
Herein presented are gold nanoparticles (AuNPs) used for the transport of medications to mucous membranes. The AuNPs are ultra-stable in that they withstand freeze-drying and heating treatments without noticeable change in their structur...  
WO/2018/056905A1
The present invention relates to co-crystals comprising the Nuclear receptor related 1 protein-ligand binding domain (Nurr1-LBD) and a cyclopentenone prostaglandin. Also provided are methods of identifying or designing Nurr1-modulating l...  
WO/2017/195762A1
The present invention relates to: a novel prostaglandin derivative having an alkynyl group in a ω-chain, particularly a novel prostaglandin derivative having a double bond at position-2 and also having an alkynyl group in a ω-chain; an...  
WO/2017/182465A1
It is provided a process for the preparation of bimatoprost, which comprises: a) reacting a compound of formula (III) with ethylamine in the presence of a suitable solvent; and b) deprotecting compound obtained in step a) to obtain bimat...  
WO/2017/093770A1
The subject of the invention is a novel process for the preparation of Carboprost tromethamine salt where alkylation the enone of the general formula (II) is carried out in the presence of a chiral auxiliary in aprotic solvent with a Gri...  
WO/2017/093771A1
The subject of the invention is a process for the preparation of Latanoprostene bunod of formula (I) with a purity higher than 95% where chromatography is used applying normal phase gravity silicagel column chromatography where the used ...  
WO/2016/155906A1
The present invention relates to 15-nitrooxyderivatives of fluprostenol, their use for the treatment of glaucoma and ocular hypertension and formulation containing 15-nitrooxyderivatives of fluprostenol.  
WO/2016/156104A1
The present invention relates to 15-nitrooxyderivatives of latanoprost and 15-nitrooxyderivatives of latanoprost free acid, their use for the treatment of glaucoma and ocular hypertension and formulation containing 15-nitrooxyderivatives...  
WO/2016/090461A1
The present invention relates to crystalline 1-adamantanamine salts, and polymorphic forms thereof, of prostaglandin analog intermediates of formula 3a, 4a and 6a, useful in the preparation of Tafluprost and Lubiprostone and processes fo...  
WO/2015/187847A1
Disclosed are methods and compositions for treating a patient having chronic myelogenous/myeloid leukemia (CML). The methods utilize and the compositions include prostaglandin El (PGE1) or Misoprotol.  
WO/2015/175984A1
Described herein are compounds which can be used in topical liquids, creams, or other dosage forms such as solids, for reducing intraocular pressure, treating glaucoma, growing hair, treating wounds, or other medical and/or cosmetic uses.  
WO/2015/136317A1
The subject of the invention is a process for the preparation of high purity prostaglandin acid of the general formula II wherein the bonds marked with dotted lines represent single or double bonds wherein the double bonds may be cis- or...  
WO/2014/203278A3
The present invention relates to a novel process for the preparation of (1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-[(3S)- 3-hydroxyoctyl]-1H-benz[f]inden-5-yl]oxy]acetic acid represented by structural formula-1 and also its ph...  
WO/2014/106204A1
The present invention provides tromethamine salt of 7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopen tyl]-hept-5-enoic acid in crystalline and amorphous form. This compound is may also be referred to as "tromethamine salt of ...  
WO/2014/083367A1
The subject of the invention is process the preparation of travoprost of formula (I) characterized by that the free acid of formula (II) is a. ) activated with 2-chloro-l,3-dimethylimidazolinium chloride (DMC) and the resulting activated...  
WO/2014/040457A1
An intermediate of formula (V) used for preparing limaprost of formula (I), preparation method thereof, and preparation method of limaprost therefrom. The present preparation method of limaprost from the intermediate of formula (V) inclu...  
WO/2014/023256A1
A method for synthesis of tafluprost and intermediates thereof are provided. The method involves hydroxyl-protecting reaction using a boronate ester, boronic acid or aminoborane as a reagent, carbonyl-oxidizing reaction, and hydroxyl-dep...  
WO/2013/164729A1
Provided herein is an improved, commercially viable and industrially advantageous process for the preparation of a prostaglandin derivatives and intermediates thereof, in high yield and purity.  
WO/2013/133730A1
A convergent synthesis of the prostaglandin F2α analogues, travoprost and bimatoprost, was developed employing Julia-Lythgoe olefination of the structurally advanced phenylsulfone with an enantiomerically pure aldehyde ω-chain synthon....  
WO/2013/118058A1
The present application relates to amine salts of prostaglandin analogs and their uses for the preparation of substantially pure prostaglandin analogs. Specific embodiments relate to amine salts of tafluprost and their uses for the prepa...  
WO/2013/104317A1
Provided are a crystal form B of a compound having the structure as represented by formula I, and preparation method and use thereof. The X-ray powder diffraction (XRPD) chart of the crystal form B has characteristic peaks at the followi...  
WO/2013/093528A1
The invention relates to a process for the preparation of travoprost of formula(I), comprising that, the compound of formula (II), is stereoselectively reduced, the resulting compound of formula (III), is if desired crystallized, the lac...  
WO/2013/040068A2
The presently disclosed subject matter provides methods of preparing synthetic prostacyclin analogues, including Beraprost, either as racemic mixtures or as single stereoisomers. Also provided are novel synthetic intermediates for use in...  
WO/2013/040068A3
The presently disclosed subject matter provides methods of preparing synthetic prostacyclin analogues, including Beraprost, either as racemic mixtures or as single stereoisomers. Also provided are novel synthetic intermediates for use in...  
WO/2013/021935A1
The present invention provides a compound which can be injected into a joint cavity which is an affected part of cartilage disorders and can be accumulated in the joint cavity to exert the pharmacological effect thereof in a sustained ma...  
WO/2012/164324A1
The subject of the invention is process for the preparation of the prostaglandin amides of the general formula I, - where in the formula the bonds marked with dotted lines may be single or double bonds, in the case of double bounds at po...  
WO/2012/164324A9
The subject of the invention is process for the preparation of the prostaglandin amides of the general formula I, - where in the formula the bonds marked with dotted lines may be single or double bonds, in the case of double bounds at po...  
WO/2012/146085A1
Disclosed is an intermediate (structural formula I) for synthesizing prostaglandin medicines and preparation method therefor. The intermediate is used for synthesizing prostaglandin medicines, such as bimatoprost, travoprost, latanoprost...  
WO/2012/139164A1
The present invention relates in general to polymer-drug conjugates. In particular, the invention relates to polymer-drug conjugates wherein the conjugated drugs are selected from prostaglandins and substituted prostaglandins, to a metho...  
WO/2012/112451A1
Provided herein, inter alia, are prodrugs of bimatoprost, methods of using the same and compositions including the same.  
WO/2012/011128A1
A process for preparing the prostaglandin derivatives is provided, wherein the benzoyl and p-nitrobenzoyl groups are used as the hydroxyl protective groups. A pharmaceutical composition comprising the prostaglandin derivatives is also pr...  
WO/2012/010089A1
Disclosed is a crystal of carboprost tromethamine as represented by Formula (I). The crystal has in the X-ray diffraction pattern at angle 2θ the following characteristic peaks: 6.6±0.2, 9.9±0.2, 18.5±0.2°, and 20.1±0.2°. Furtherm...  
WO/2011/159740A2
The present invention generally relates to synthetic methods for preparing tetranor-prostaglandin D, J, E, A, and F metabolites.  
WO/2011/159740A3
The present invention generally relates to synthetic methods for preparing tetranor-prostaglandin D, J, E, A, and F metabolites.  
WO/2011/154754A1
The invention pertains to the use of the compounds of the general formula (I) and their pharmaceutically acceptable salts for reduction of inflammation, (I) wherein R represents a hydrogen atom, hydroxyl group, amino group or NH-R' group...  
WO/2011/120474A8
The invention relates to a method for inhibiting the replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, specifically the proteins that form part of the cytoskeletal intermediate f...  
WO/2011/120474A1
The invention relates to a method for inhibiting the replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, specifically the proteins that form part of the cytoskeletal intermediate f...  
WO/2011/120474A9
The invention relates to a method for inhibiting the replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, specifically the proteins that form part of the cytoskeletal intermediate f...  
WO/2011/095990A3
The present invention discloses a process for purification of prostaglandins of formula (1) into enantiomerically pure isomer of formula (2) by reverse phase preparative HPLC, and converting said isomer into prostaglandin derivative of f...  
WO/2011/095990A2
The present invention discloses a process for purification of prostaglandins of formula (1) into enantiomerically pure isomer of formula (2) by reverse phase preparative HPLC, and converting said isomer into prostaglandin derivative of f...  
WO/2011/091513A1
There is provided a crystalline form of Lubiprostone, termed APO-II and methods for making APO-II. APO-II is a polymorphic form of Lubiprostone.  
WO/2011/063276A1
The present invention provides a new crystalline form of bimatoprost, designated as crystalline form II. This new crystalline form is the most stable form known to date of bimatoprost. Moreover, it has been found that bimatoprost crystal...  
WO/2011/055377A1
This invention relates to novel process for the preparation of prostaglandin compounds having formula (K), wherein R is selected from the group consisting of C1-C7 alkyl; C7-C17 aralkyl wherein the aryl group is unsubstituted or substitu...  
WO/2011/050638A1
The crystalline form A of bimatoprost of formula I, its preparation method and use are provided. There are characteristic peaks where diffraction angles 2θ are 3.2±0.2°, 5.5±0.2°, 11.4±0.2°, 16.7±0.2°, 17.6±0.2°, 19.9±0.2°, ...  
WO/2011/005505A2
The present invention provides a method for the purification of a prostaglandin by supercritical fluid chromatography, said method comprising the use of a stationary phase and a mobile phase comprising carbon dioxide, provided that when ...  
WO/2011/005505A3
The present invention provides a method for the purification of a prostaglandin by supercritical fluid chromatography, said method comprising the use of a stationary phase and a mobile phase comprising carbon dioxide, provided that when ...  
WO/2010/109476A3
The present invention relates to an improved process for the preparation of prostaglandin and prostaglandin analogues, particularly PGF2α derivatives.  
WO/2010/109476A2
The present invention relates to an improved process for the preparation of prostaglandin and prostaglandin analogues, particularly PGF2a derivatives.  
WO/2010/097672A1
The invention concerns a new process for the preparation of prostaglandin derivatives, in particular prostaglandin F2α derivatives, for example bimatoprost, latanoprost and travoprost, the new intermediates of said process and their use...  
WO/2010/096123A2
The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.  

Matches 1 - 50 out of 2,634